Pattern of recurrence and efficacy of salvage therapy after relapse in locally advanced esophageal carcinoma treated with preoperative chemoradioth...

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter M. Oliva
Citation Annals of Oncology (2016) 27 (2): 1-85. 10.1093/annonc/mdw199
Authors M. Oliva1, M. Saigí1, L. Aliste2, G. Hormigo1, M. Calvo1, &. Serra1, H. Aranda3, C. Bettonica4, N. Virgili4, J. Robles5, N. Romero1, M. Boladeras Ana1, J. Paúles Maria3, B. Gornals Joan1, L. Farran3, M. Galán1
  • 1Interdisciplinary Committee of Esophagogastric Tumours, Institut Català d'Oncologia (ICO), L'Hospitalet, IDIBELL, Hospitalet de Llobregat, Spain, /
  • 2Catalonian Cancer Strategy, Department of Health, Government of Catalonia, Hospitalet de Llobregat, Spain, /
  • 3Interdisciplinary Committee of Esophagogastric Tumours, Hospital Universitari Bellvitge (HUB), L'Hospitalet, IDIBELL, Hospitalet de Llobregat, Spain, /
  • 4Interdisciplinary Committee of Esophagogastric Tumours, Hospital Universitari Bellvitge (HUB), Hospitalet de Llobregat, Spain, /
  • 5PET Scan-IDI Bellvitge, Interdisciplinary Committee of Esophagogastric Tumours, Hospital Universitari Bellvitge (HUB), l'Hospitalet, IDIBELL, Hospitalet de Llobregat, Spain, /

Abstract

Patients (pts) with locally advanced esophageal carcinoma (LAEC) benefit from preoperative chemo-radiotherapy (NA CRT) followed by surgery. However, half of them will relapse within the first 2 years, having limited treatment options. Moreover, adenocarcinoma (ADC) and squamous cell carcinoma (SCC) are thought to represent two different diseases which might differ in terms of recurrence. Our aim is to analyze the characteristics and outcome of pts who relapse.